Wednesday, May 1, 2013
PATENTED DRUG LAUNCHES MAY BE DELAYED IN INDIA
Launch of patented drugs in India could be
delayed due to the government's "thought process on linking patented
drug prices to the country's per-capita income", according to a report
by consultancy firm Deloitte. "The recent government thought process on
linking patented drug prices to the country's per-capita income in
relation to certain developed markets could result in delayed patented
drug entry into India," the report said. As per the 2013 Global life
sciences outlook by Deloitte, the debate over compulsory licensing
remains a contentious issue in India, while innovator pharmaceutical
firms will also face several challenges such as margin pressure from
pharma generics and complex regulatory policies. In the recent
past, India has witnessed some major developments related to patented
drugs. In a major landmark judgement in April this year, the Supreme
Court had rejected Swiss pharma giant Novartis's plea for patent
protection on cancer drug Glivec and to restrain Indian firms from
making generic copies of the drug. Earlier in March this year,
Intellectual Property Appellate Board (IPAB) had upheld compulsory
license granted to domestic firm Natco Pharma allowing it to produce
cheaper generic versions of Nexavar, a patented drug of multinational
Bayer Corporation, used for treating the liver and kidney cancers. Last
year, Natco was allowed to manufacture and sell generic Nexavar at a
price not exceeding Rs 8,880 for a pack of 120 tablets required for a
month's treatment as compared to a huge Rs 2.80 lakh per month charged
by Bayer. Spelling other challenges in the India pharmaceuticals
market, Deloitte said low insurance penetration was resulting in a
self-pay market with considerable affordability and access barriers,
apart from a lack of consumer awareness and education and heavy market
fragmentation. Despite challenges, the outlook for 2013 is promising,
Deloitte said. "There is an inherent demand for health care products
and services due to India's large patient base and increasing awareness
of wellness by its growing population," it said. Second, both the
government and private sectors are increasing their initiatives to
improve health/well-being and enhance population coverage (including
access to rural and low-tier cities), it added.
Subscribe to:
Post Comments (Atom)
ఐపిఓల సందడి, నిధుల సేకరణ దండి
ప్రైమరీ మార్కెట్లో ఈ ఏడాది (2024) ఐపీఓ సందడి జోరుగా ఉంది. ఏడాది మొత్తం మీద 90 ప్రధాన ఇష్యూల ద్వారా కంపెనీలు రూ.1.6 లక్షల కోట్లు సమ...
-
fo r April 25, 2019 Closing Subdued Tithi : Chaitra Krishna Saptemi Nakshatra : Poorvashadha Persons born in Mrigasira, ...
-
మార్కెట్ విలువలో బిఎస్ఇ కొత్త రికార్డు బొంబాయి స్టాక్ ఎక్స్ఛేంజిలో (బిఎస్ఇ) లిస్టింగ్ అయిన కంపెనీల ఉమ్మడి మార్కెట్ విలువ మంగళవారం (202...
-
దేశంలో సుజుకి మోటార్ కార్పొరేషన్ (ఎస్ఎంసి) మూడు కోట్ల కార్ల ఉత్పత్తి మైలురాయిని దాటింది. అయితే తన మాతృదేశంలో ఈ మైలురాయిని సాధించిన సమయం...
No comments:
Post a Comment